Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
all-trans retinoic acid + vincristine + dactinomycin + cyclophosphamide + anlotinib
- Development stage
- Unknown
- Lead developer
- Fudan University
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination therapy, developed by Fudan University, is a multi-agent regimen designed for the treatment of intermediate-to-high-risk rhabdomyosarcoma. It integrates the standard-of-care VAC chemotherapy backbone (vincristine, dactinomycin, and cyclophosphamide) with all-trans retinoic acid (ATRA) and the multi-target tyrosine kinase inhibitor anlotinib. ATRA is included to promote the differentiation of myogenic precursor cells, which are often arrested in an undifferentiated state in rhabdomyosarcoma. Anlotinib provides targeted inhibition of angiogenesis and tumor cell signaling by blocking VEGFR, FGFR, PDGFR, and c-Kit. The regimen is currently being evaluated in a Phase II clinical trial to determine if the addition of differentiation therapy and anti-angiogenic agents can improve progression-free and overall survival in patients with advanced rhabdomyosarcoma who have not received prior systemic treatment.
- Other names
- ATRA + VAC + AnlotinibATRA plus VAC plus anlotinib
02
Targets
RARA (Retinoic acid receptor alpha)FGFR (FGFR family)PDGFRA (Platelet-derived growth factor receptor alpha)RARB (Retinoic acid receptor beta)KIT (c-KIT proto-oncogene receptor tyrosine kinase)TUBB (Tubulin (alpha and beta subunits))DNAVEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on all-trans retinoic acid + vincristine + dactinomycin + cyclophosphamide + anlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on all-trans retinoic acid + vincristine + dactinomycin + cyclophosphamide + anlotinib.